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Diversity oriented biosynthesis via accelerated
evolution of modular gene clusters
Aleksandra Wlodek 1, Steve G. Kendrew2,8, Nigel J. Coates1,2, Adam Hold1, Joanna Pogwizd1, Steven Rudder1,
Lesley S. Sheehan1,2, Sarah J. Higginbotham1, Anna E. Stanley-Smith1,2, Tony Warneck2,
Mohammad Nur-E-Alam2,9, Markus Radzom2,10, Christine J. Martin2, Lois Overvoorde1,
Markiyan Samborskyy 3, Silke Alt4, Daniel Heine4, Guy T. Carter5, Edmund I. Graziani5,11, Frank E. Koehn5,
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Lucinda Steward6, Isobel H. Norville7, Mitali Sarkar-Tyson7,12, Steven J. Moss1,2, Peter F. Leadlay3,
Barrie Wilkinson 1,2,4 & Matthew A. Gregory 1,2
Erythromycin, avermectin and rapamycin are clinically useful polyketide natural products
produced on modular polyketide synthase multienzymes by an assembly-line process in
which each module of enzymes in turn speciﬁes attachment of a particular chemical unit.
Although polyketide synthase encoding genes have been successfully engineered to produce
novel analogues, the process can be relatively slow, inefﬁcient, and frequently low-yielding.
We now describe a method for rapidly recombining polyketide synthase gene clusters to
replace, add or remove modules that, with high frequency, generates diverse and highly
productive assembly lines. The method is exempliﬁed in the rapamycin biosynthetic gene
cluster where, in a single experiment, multiple strains were isolated producing new members
of a rapamycin-related family of polyketides. The process mimics, but signiﬁcantly accel-
erates, a plausible mechanism of natural evolution for modular polyketide synthases. Detailed
sequence analysis of the recombinant genes provides unique insight into the design principles
for constructing useful synthetic assembly-line multienzymes.
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Reduced polyketide natural products (NPs) produced bymodular polyketide synthase (PKS) assembly lines are arich source of clinically approved products including
antibacterial (erythromycin, ﬁdaxomicin), immunosuppressive
(rapamycin, FK506) and anthelminthic (avermectin) agents1.
These structurally complex NPs are biosynthesized through the
decarboxylative condensation of (alkyl)malonyl-CoA extender
units on modular PKSs in a process similar to that of fatty acid
biosynthesis2. The genetic basis of reduced polyketide biosynth-
esis was ﬁrst described in 1990–19913, 4 and shown to depend
upon the expression of highly repetitive genes encoding large
multifunctional enzymes containing a separate module of enzy-
matic activities for every round of polyketide chain extension.
Each module comprises the individual catalytic domains required
for each chemical step in the process. This direct relationship
between the sequence of PKS-encoding genes and the structure of
the product molecule immediately suggested the potential for
rational genetic modiﬁcation to yield strains capable of producing
analogues of predictable structure, and although then many
groups have attempted to bioengineer these systems with varying
success5–7. Several examples of targeted in vivo analogue pro-
duction at reasonable titre have been described8–10, although a
reduction in productivity often accompanies the generation of
hybrid or modiﬁed PKSs11–13. This approach is most suited to
producing focussed libraries closely related in structure to the
parent molecule, limiting its industrial application to lead opti-
misation. There are few published examples of its use for gen-
erating novel products capable of hitting new targets14. Despite
the publication of detailed structural information for these
enzymes15, 16, one of the major barriers to progress in engineering
modular PKSs has been the lack of an experimental knowledge
base to guide the optimal choice of splice points to generate
hybrid PKSs17, 18.
During an experiment to rationally bioengineer the rapamycin
biosynthetic gene cluster (BGC), by replacing enzymatic domains
within the PKS, we made the serendipitous observation that,
instead of the expected product, a variety of unexpected analo-
gues (rapalogs) were produced at good to excellent titres by the
various progeny isolated from the experiment after selecting for a
secondary crossover event (allelic exchange). Following isolation
and structure elucidation it became clear that these compounds
were related to rapamycin, but consisted of molecules lacking
between 2 and 12 carbon atoms from the polyketide chain
backbone, or, in one instance, containing 2 carbons extra. Bio-
synthetic considerations suggested that these would arise from
truncated or expanded PKS multienzymes, respectively, and this
was conﬁrmed by whole-genome sequencing of the relevant
mutant strains. These observations were reproducible for the
rapamycin PKS, and could be recapitulated in a second modular
PKS-encoding BGC (for the antibiotic tylosin).
We now report the structures of these rapalogs and the gene
sequences encoding their biosynthesis. A mechanism for this
process is proposed based on stochastic recombination between
repeating regions of high-sequence homology that occur in the
genes encoding for modular biosynthetic systems. This is driven
by insertion, through homologous recombination, of a plasmid
encoding a temperature sensitive, high-copy replicon into the
modular PKS-encoding genes under non-permissive conditions.
On lowering the temperature to that permissive of replication, the
integrated replicon causes an otherwise catastrophic event that is
resolved by loss of the region comprising the integrated replicon
after homologous recombination between ﬂanking PKS-encoding
genes.
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Fig. 1 Pathway for the biosynthesis of 1 and organisation of the rapamycin PKS. The repetitive, modular nature of each PKS protein is clearly evident. The
circles represent individual catalytic domains: CoL=CoA ligase like; KS= β-ketoacyl-ACP synthase; AT= acyltransferase; DH= dehydratase; ER= enoyl
reductase; KR= β-ketoacyl-ACP reductase; ACP= acylcarrier protein. Filled circles represent inactive domains. hCHCA= trans-4-
hydroxycyclohexanecarboxylic acid which is fed to the strain ISOM-4010 to initiate the biosynthesis of 1 and rapalogs 2–8
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Results
Bioengineering of the rapamycin PKS. Our initial target was to
replace inactive domains from module 3 of the rapamycin PKS
with active domains from module 11 and 13 to yield strains
capable of producing 32-desketorapamycin. This experiment was
performed using the rapamycin ΔrapK mutasynthesis strain
Streptomyces rapamycinicus ISOM-4010 (previously BIOT-4010)
19. This strain produces rapalogs only in the presence of exo-
genously added non-native starter units, for example feeding
trans-4-hydroxycyclohexanecarboxylic acid (hCHCA) leads to
production of 39-desmethoxyrapamycin, 1 (Fig. 1)19, 20. To carry
out the experiment, we made use of the Escherichia coli-
Streptomyces shuttle plasmid pKC113921. This contains the
temperature sensitive pSG5 replicon22, which enables a three-step
protocol whereby the plasmid (containing the appropriate DNA
to enable the desired domain replacement via an allelic replace-
ment approach) is ﬁrst conjugated into the actinomycete strain
from E. coli. Maintenance of the apramycin resistant ex-
conjugants at a higher, non-permissive temperature (at which
the pSG5 replicon is essentially non-functional) then allows
selection of strains where the plasmid has recombined via a
region of homology into the target PKS gene. Finally, the strains
are maintained at a lower (permissive) temperature allowing
selection of apramycin sensitive colonies which have undergone a
second recombination event to lose the plasmid. However,
instead of the expected mix of domain replacement mutants and
wild-type revertants, we discovered a variety of progeny produ-
cing unexpected products.
Following fermentation of these mutants, analysis of their
culture extracts using LCMS/UV indicated a variety of
rapamycin-like products that were only generated in the presence
of exogenous hCHCA. All compounds exhibited the distinctive
rapamycin UV chromophore but had m/z values inconsistent
with the originally targeted rapalog. This phenomenon was
readily reproducible and the mutants were stable. To quantify the
distribution of phenotypes we repeated the experiment, using the
same plasmid, and 667 progeny were isolated, fermented with
hCHCA and their culture extracts analysed. Of these, 22.5% (150)
produced new rapalogs, 63.1% (421) produced 1 and 14.4% (96)
produced no obvious molecules with the rapamycin chromo-
phore. Among the mutants producing new rapalogs, we identiﬁed
twenty apparent variations on the rapamycin structure on the
basis of HPLC retention times, m/z values and MS/MS
fragmentation patterns.
Based on this analysis, the fermentation of seven mutants, each
producing a different rapalog, was scaled up and the products
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Fig. 2 Structures of isolated rapalogs (2–8) encompassing a range of macrolactone ring sizes. C32 of rapamycin is labelled and is the site of the chemical
change expected from the attempted rational bioengineering experiment via a reductive loop swap
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isolated at the 10−100s of milligram scale. Their structures were
then determined through a combination of 2D NMR and high-
resolution LCMS/MS analysis (Supplementary Note 1). As shown
in Fig. 2, these rapalogs include molecules with both truncated
(3–7) and expanded (8) macrolactone rings, alternative cycliza-
tion patterns (3), and linear molecules (2). The structures were
consistent with biosynthesis occurring on altered rapamycin PKSs
consisting of reduced or increased numbers of extension modules.
Given the tandem repetitive nature of genes encoding modular
PKSs, this immediately suggested a recombination-based process
in which the genes encoding the rapamycin PKS had undergone a
range of deletion or duplication events.
To further probe the utility of these mutants, a selection of ﬁve,
each generating a different rapalog, were fermented in the
presence of hCHCA or one of 32 further starter unit acid
analogues leading to the mutasynthesis of 100s of new rapalogs as
ascertained by LCMS/UV analysis (Supplementary Note 2).
Biological activity of new rapalogs. The unexpected observation
that a single experiment could generate rapalogs of diverse che-
mical structure prompted us to investigate, ﬁrst, whether these
unique molecules might bind to a new target or show altered, yet
valuable, biological activity. Selected rapalogs were ﬁrst examined
for their ability to inhibit both the peptidyl-prolyl isomerase
(PPIase) inhibitory activity of the FK506-binding protein
(FKBP12)23, using a well understood biochemical assay, and
modulation of the mTORC1 pathway activity, via the validated
inhibition assay of p-S6 formation24 (Table 1).
As anticipated, the potency of mTORC1 pathway inhibition
decreased as the size of the macrocycle ring was reduced. Despite
all of the tested molecules retaining the triene moiety, which
forms a key interaction with the FRAP domain of mTOR25,
reducing ring size will signiﬁcantly affect the triene geometry
which is known to be critical for this interaction. However,
despite a reduction in inhibitory activity of 3–4 log units, some of
the rapalogs still retained sub-micromolar inhibitory activity,
suggesting they may be useful for enabling more subtle
modulation of mTORC1 functions.
In contrast, the less-immunosuppressive rapalogs retained
potent inhibition of FKBP12 until six or more carbon atoms were
removed from the macrocyclic ring. This is consistent with the
observation that all of these compounds retain the key tricarbonyl
region adjacent to the pipecolate moiety which, together,
encompass the FK506-binding domain of rapamycin25. Based
on these observations we examined the ability of AE-derived
rapalogs to inhibit the FKBP12-like macrophage infectivity
potentiator (MIP) proteins which are key virulence determinants
for several pathogenic gram-negative bacteria including Legio-
nella pneumophila, Burkholderia pseudomallei and Coxiella
burnetii26–28. These experiments identiﬁed 7 as a potent inhibitor
(IC50< 25 nM) of the PPIase activity of the MIP protein
BPSS1823 of B. pseudomallei28 (Table 1). Furthermore, 7 was
shown to increase the survival of human macrophages challenged
with B. pseudomallei.
We additionally assessed the rapalogs for antifungal activity
using a standard Saccharomyces cerevisiae MIC assay. As
expected, activity was similar to that observed for the mTORC1
pathway assay, likely through inhibition of TOR1 and TOR2.
Genetic basis of new rapalog biosynthesis. We next sought to
understand the genetic basis of the AE-generated chemical
diversity. To achieve this, we subjected 17 mutants to whole-
genome sequencing using either single-molecule real-time
(SMRT) technology on the PacBio RSII platform, or through
sequencing of TruSeq PCR-free shotgun and Nextera matepair
libraries on an Illumina MiSeq platform. In order to understand
variation in the putative recombination events, the 17 mutants
chosen for sequencing included multiple examples producing
each of the rapalogs 2–8 at a range of titres (Supplementary
Table 1).
Analysis of the resulting assemblies revealed that any genomic
changes were conﬁned to the PKS region of the rapamycin
BGC29. In each case, new PKS architectures observed were
consistent with recombination between modules in regions of
high sequence similarity, including both deletion and duplication
events. In several examples an apparently simple deletion event
had produced a new PKS-encoding gene, frequently via
conﬂation of rapA and rapB genes, while in others the process
was more complex (Fig. 3). For example, the strain producing the
chain-extended product 8 (ISOM-4309) encodes a new PKS gene
with almost two modules deleted (most of modules 2 and 3) while
three extra modules (derived from part of module 11 and
modules 12 and 13 from rapC) are inserted into rapA. None of
the 17 sequenced PKS gene clusters had identical DNA sequences.
In some cases, the overall architecture was similar, but with
different junctions seen at the contraction point, for example
comparison of ISOM-4180 and ISOM-4184, which have junctions
843 bp apart. In another case (ISOM-4291 and ISOM-4280), the
63 bp region of the likely junction was identical, although as both
strains were progeny from different lines they had arisen through
independent recombination events.
On closer examination, it became clear that the inter-modular
PKS junction sites of the higher-titre mutants were frequently
located either internal to DNA coding for the ketosynthase (KS)
or acyltransferase (AT) domains, or in a region just upstream of
DNA coding for the acylcarrier protein (ACP) domain that
corresponds to a ﬂexible linker region (Fig. 4). Analysis of rapalog
titres revealed that 14 of the 17 mutants had titres >60 μM, as
compared to the mean titre of 1 (193.3± 49.2 μM) from control
fermentations (Supplementary Table 1). One notable strain that
fell outside this window was ISOM-4309 (11.7± 0.2 μM), the only
strain producing a ring expanded product. Interestingly, the
junctions which fall within the region encoding the AT domains
join modules that both contain either malonate or methylmalo-
nate encoding ATs. We anticipate that analysis of these and
future AE-generated hybrid modules will provide valuable
guidelines for the rational bioengineering of modular PKSs.
Generality and mechanism of the AE process. Encouraged by
these results, we attempted to replicate the AE process in a second
modular PKS encoding BGC. For this we chose the tylosin PKS of
Streptomyces fradiae NRRL 2702, as the organism is amenable to
genetic modiﬁcation and tylosin has a strong UV chromophore to
aid preliminary chemical analysis.
Table 1 Biological activity of rapalogs
Compound ID Module
organisation
FKBP12 Ki
(nM)
p-S6
IC50
(nM)
S. cerevisiae
MIC (μgmL−1)
Rapamycin Natural 5.4 <1 <0.25
1 Natural 2.5 N/A <0.25
8 +1 6.5 N/A <2
7 −1 7.9 100 <2
5 −3 370 300 <64
3 −5 460 >1900 >64
2 −6 >1000 1000 >64
Comparison of FKBP12 PPIase inhibition, mTORC1 pathway inhibition (p-S6) and S. cerevisiae
MIC values for a selection of rapalogs.
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To simplify the AE procedure, and in contrast to the
rapamycin example, pKC1139-based plasmids containing single
regions of homology (~ 2 kb) to each of the modules in the tylosin
PKS were generated, rather than constructs designed to mediate
an allelic replacement. We then carried out an analogous genetic
procedure to that used for modiﬁcation of ISOM-4010 above
(Methods section) and identiﬁed progeny that produced tylosin-
related analogues instead of tylosin as determined by LCMS/UV
analysis. Following whole-genome sequencing (Illumina sequen-
cing) we identiﬁed ten different examples of tylosin PKS
rearrangements that were analogous to those observed for the
rapamycin PKS, including deletion of modules 4−6 (in ﬁve cases),
Arrangement of first two PKS genesStrain no. Chemical structure of major product
RapA RapB
L 1 2 3 4 5 6 7 8 9 10
RapB
L 1 H 13 4 5 6 7 8 9 10
RapA
L 1 2 H
RapB
6 7 8 9 10
RapBRapA
L 1 H 4 5 6 7 8 9 10
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5 6 7 8 9 10
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L 1 2 6 7 8 9 10
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Fig. 3 Comparison of the chemical structures isolated from each of the novel strains and the rapamycin PKS modular alignment for each of the sequenced
PKS genes. Circles show enzymatic domains in each module. Modules 11–14 encoded by RapC are not shown
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deletion of modules 1 to 4 (in two cases), deletion of modules 2−6
(in three cases), and a deletion between the loading domain and
module 6 in one case (Supplementary Fig. 1).
At this point, we had come to believe that the presence of the
temperature sensitive, high-copy replicon of pKC1139 was likely
to be an essential part of the AE process. Therefore, we repeated
the AE procedure in the tylosin system but included a control
plasmid based on the suicide vector pKC113221, which is similar
to pKC1139 but lacks the pSG5-derived replicon. Both plasmids
contained the same ~ 2 kbp fragment of DNA from module 2 of
the tylosin PKS encompassing the KR and ACP domains. After
performing the AE procedure with these plasmids in parallel, 67%
of the progeny isolated after transformation with the pKC1139-
based plasmid (n= 30) produced new tylosin analogues analo-
gous to those described above. In contrast, when the pKC1132-
based control plasmid was used, 70% (21) reverted to tylosin
production and 30% (9) were non-producers; no progeny from
the control experiment produced new tylosin analogues. These
data lead us to conclude that the pSG5-based replicon of
pKC1139 may be critical to the AE process we describe.
Discussion
In nature, modular PKSs evolve via processes that comprise gene
and intra-gene (e.g., module) duplications, speciation including
mutation and homologous recombination (both inter-BGC and
intra-BGC), and horizontal gene/BGC transfer events18, 30–32.
Indeed, there are several families of known natural products,
characterised by structurally related analogues comprising a range
of macrocyclic ring sizes, for which the biosynthetic, evolutionary
origins are likely to involve a process involving the deletion or
duplication of PKS modules. Examples include the polyenes,
marginolactones and macrodiolides33. Recently, Abe and co-
workers examined the evolutionary relationship of giant modular
PKS gene sets that encode for the biosynthesis of several struc-
turally related aminopolyol polyketides (each between 25–30
modules)34. The authors concluded that, during evolution, the
modular unit for duplication or deletion is likely to follow the
non-canonical domain order AT through to KS, rather than the
canonical KS through to AT. This should not be surprising given
the knowledge that trans-AT PKSs (which do not have embedded
AT domains), show a strong correlation between the chemical
structure of the substrate produced by the processing enzymes of
a module and the nature of the downstream KS domain35, 36. It is
also consistent with observations of downstream KS selectivity
made during PKS bioengineering37, 38 and morphing39, 40
experiments.
The process we report here mimics, on a laboratory timescale, a
plausible mechanism of natural evolution for modular PKS genes
involving recombination between separate biosynthetic genes or
BGCs. We ﬁnd that the majority of new PKSs formed are func-
tional, and that the module junction sites for the most productive
PKSs are not canonical but occur intra-module, generally within
KS or AT sequences, or in the inter-domain linker region
upstream of ACP domains. Given these considerations we refer to
the laboratory induced process as Accelerated Evolution (AE).
Moreover, it is important to stress that in a single experiment the
AE process generates a multiplicity of new PKS-encoding pro-
geny and therefore enables the diversity orientated biosynthesis of
numerous new polyketide molecules.
Recombination and repair in Streptomyces bacteria are rela-
tively poorly understood41, 42. It is our current hypothesis that an
essential component of the AE process is localised genetic
instability caused by activation of the pSG5 temperature sensitive
replicon while still integrated into the genome. Lowering the
temperature, so that it is permissive for function of the pSG5
replication, likely generates a new replication fork which can
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collide with the natural fork leading to temporary arrest. Such
events can be catastrophic, and in bacteria and eukaryotes are
often associated with genome instability and rearrangements43–
46. Several mechanisms can act to resolve this kind of damage
including homologous recombination and non-homologous end
joining42, 47, 48. For the case in point, the highly repetitive nature
of the ﬂanking PKS genes provide the ideal template for repair via
homologous recombination with concomitant loss of the genomic
region encoding the pSG5 replicon. This mechanism is entirely
consistent with the data obtained from sequencing the 17 rapalog
producing mutants.
In summary, although the precise molecular mechanism of the
AE process remains to be determined, our ﬁndings represent a
new paradigm in the search for new and valuable chemical
entities based on natural products. Experiments to extend the AE
approach to many additional natural product biosynthetic path-
ways are in progress.
Methods
Bacterial strains and plasmids. Streptomyces rapamycinicus ISOM-4010 (pre-
viously BIOT-4010; Streptomyces rapamycinicus NRRL5491 ΔrapK19), S. fradiae
NRRL 2702, and their derivatives were maintained on MAM agar. The pKC1139-
derived21 constructs able to induce deletion or expansion of the PKS modules were
maintained in E. coli DH10B and transferred from E. coli ET12567/pUZ8002 to S.
rapamycinicus ISOM-4010 or S. fradiae NRRL 2702 according to standard conjugal
transfer methods49.
Plasmid generation for Streptomyces rapamycinicus. The AE plasmids for the
rapamycin PKS contained the particular regions of the gene cluster intended to act
as homology regions for recombination and were ampliﬁed from Cos2529 (primers
listed in Supplementary Table 2). Each of the ampliﬁed products was cloned into a
separate pUC19 backbone. The ﬁrst fragment was then excised using EcoRI and
ApaI, and the second fragment using ApaI and XbaI. Both were then ligated with
pUC19 between EcoRI and XbaI, to form an intermediate plasmid 1. The third
fragment was excised using XbaI and PstI, and the fourth using PstI and HindIII,
and ligated together with pUC19 between XbaI and HindIII sites. This plasmid was
designated intermediate plasmid 2.
Intermediate plasmid 1 was digested with EcoRI and XbaI, to form the ﬁrst
region of homology. The second region of homology was retrieved from
intermediate plasmid 2 through digestion with XbaI and HindIII. These two
fragments were ligated together with pUC19 that had been digested with EcoRI and
HindIII. The resulting vector was then digested with NheI and BglII to insert the
desired reductive loop. Two alternative loops were used, one from module 13 of the
rapamycin PKS, and one from module 11. The reductive loop of module 13 of the
rapamycin cluster was excised from plasmid pPF13750 using NheI and BglII, and
the reductive loop of module 11 was excised from plasmid pWV16551. The
resulting cassettes were cloned into to pKC1139 between EcoRI and HindIII sites.
The resulting plasmids were named pSGK210 (containing rapamycin PKS module
13 loop) and pSGK212 (containing rapamycin PKS module 11 loop). These
plasmids were transferred to S. rapamycinicus ISOM-4010 as described below.
AE procedure in Streptomyces rapamycinicus. Plates of S. rapamycinicus ISOM-
4010 transformed49 with plasmids pSGK210 and pSGK212 were incubated at 37 °C
until single exconjugant colonies were visible. Colonies were transferred to MAM
agar (Wheat Starch, 10 g L−1; Corn steep powder, 2.5 g L−1; Yeast extract, 3 g L−1;
CaCO3, 3 g L−1; FeSO4, 0.3 g L−1; Agar, 20 g L−1) containing apramycin (50 μg mL
−1) and nalidixic acid (50 μg mL−1), and were incubated at 37 °C for 7 days.
Approximately 10–15 of the strains were then transferred to solid ISP3 agar
(Oatmeal, 20 g L−1; Bacto Agar, 18 g L−1; Trace element solution, 1 mL L−1 (1 g L−1
each of FeSO4·7H2O, MnCl2·4H2O and ZnSO4·7H2O)) lacking antibiotics and
incubated at 37 °C for ~3 days before transferring to ISP3 agar for a further 3 or
4 days. A ﬁnal round of subculture at 37 °C on ISP3 agar was performed before
transferring again to ISP3 agar and incubating at 28 °C to allow the strain to
sporulate (~10–14 days). Spores were harvested in 20% glycerol and a dilution
series prepared in water and spread onto ISP3 agar before incubating at 28 °C.
Once individual sporulating colonies were visible they were replica plated to ISP3
agar with and without apramycin to assess loss of plasmid. Strains that had lost the
marker were then tested by fermentation, extraction and HPLC analysis as
described below, to assess whether they produced 1 (i.e., had reverted to original
strain). Among the strains that no longer produced 1, strains producing new
compound peaks with the rapamycin chromophore were identiﬁed.
Generation of AE plasmids for use in Streptomyces fradiae. For tylosin AE
experiments regions of the tylosin PKS were ampliﬁed from genomic DNA (iso-
lated using FastDNA SPIN Kit for Soil—MP Biomedicals) using the primer pairs
IR001_3 to IR001_8 listed in Supplementary Table 2. Each of the ampliﬁed pro-
ducts was introduced into pKC1139 which had been digested with HindIII and
EcoRI using InFusion cloning (Clontech). Construct pIR001_3 contains a 2052 bp
fragment ampliﬁed from to module 3 (including KS and AT domains). Construct
pIR001_4 contains a 2002 bp fragment ampliﬁed from module 5 (including KR and
ER/ACP domains). Construct pIR001_6 contains a 2091 bp fragment ampliﬁed
from module 1 (including KR and ACP domains). Construct pIR001_7 contains a
2091 bp fragment ampliﬁed from module 3 (including KR and ACP domains).
Construct pIR001_8 contains a 2070 bp fragment ampliﬁed from module 4,
including KR and ACP domains. These plasmids were transferred to S. fradiae
NRRL 2702 by standard conjugation methods as described below.
AE procedure in Streptomyces fradiae. Plates of S. fradiae NRRL 2702 trans-
formed49 with plasmids generated as described above, were incubated at 37 °C until
single exconjugant colonies were visible. Colonies were transferred to MAM agar
containing apramycin (50 μg mL−1) and nalidixic acid (50 μg mL−1), and were
incubated at 37 °C for 7 days. Approximately 20 of the strains were then transferred
to MAM agar with apramycin and nalidixic acid, and when stabilised were tested
for production of tylosin to select primary integrants lacking tylosin production (as
described below). The non-producers were transferred to MAM agar lacking
antibiotics and incubated at 37 °C for ~7 days before transferring to MAM agar for
a further 3 or 4 days. A ﬁnal round of subculture at 37 °C on MAM agar was
performed before transferring again to MAM agar and incubating at 28 °C to allow
the strain to sporulate (~10–14 days). Spores were harvested in 20% glycerol and a
dilution series prepared in water and spread onto MAM medium before incubating
at 37 °C. When only the individual sporulating colonies were visible they were
replica plated on MAM agar with and without apramycin to assess loss of plasmid.
Strains that had lost the marker were tested by fermentation, extraction and HPLC
as described below, to assess whether they still produced tylosin (i.e., had reverted
to original strain). Among the strains that no longer produced tylosin, strains
producing new compound peaks were identiﬁed using HPLC-UV and LCMS.
Analytical fermentation of genetically engineered strains. Derivatives of S.
rapamycinicus ISOM-4010 were grown for 10–14 days on ISP3 or MAM agar. An
agar cylinder (5 mm in diameter) from each strain was used to inoculate a 50 mL
Falcon tube containing RapV7 medium19 (7 mL), and incubated at 28 °C, 300 r.p.
m. (2.5 cm throw) for 48 h. This seed culture (0.5 mL) was used to inoculate MD6
medium19 (7 mL) and the culture was incubated at 26 °C and 300 r.p.m. for 6 days;
after 24 h each culture was supplemented with hCHCA (ﬁnal concentration 2 mM).
Derivatives of S. fradiae were grown for at least 7 days on MAM agar and used
to inoculate 7 mL modiﬁed TylB medium (beet molasses, 20 g L−1; corn meal,
15 g L−1; vegetable peptone, 9 g L−1; NaCl, 1 g L−1; soy ﬂour, 13.5 g L−1; (NH4)2PO4,
0.4 g L−1; CaCO3, 2 g L−1; soybean oil, 30 g L−1; in deionised water) and incubated
at 28 °C, 300 r.p.m. (2.5 cm throw) for 7 days.
Chemical analysis of rapalogs. An aliquot of whole culture broth (0.5–0.8 mL)
was mixed 1:1 with methanol and shaken vigorously for 30 min. The sample was
centrifuged at 16,100×g, and the supernatant was analysed by HPLC with diode
array detection. The HPLC system comprised an Agilent HP1100 equipped with a
Phenomenex Gemini-NX C18 3 μm 110 Å reversed-phase column (150 × 4.6 mm)
or Phenomenex Hyperclone 3 μm BDS C18 130 Å column (150 mm × 4.6 mm)
heated to 50 °C. The gradient elution was from 55% mobile phase B to 95% mobile
phase B over 10 min followed by isocratic elution at 95% mobile phase B for 2 min;
ﬂow rate 1 mLmin−1. Mobile phase A was 10% acetonitrile:90% water, containing
10 mM ammonium acetate and 0.1% triﬂuoroacetic acid; mobile phase B was 90%
acetonitrile:10% water, containing 10 mM ammonium acetate and 0.1% tri-
ﬂuoroacetic acid. Rapalogs were identiﬁed by the presence of the characteristic
rapamycin triene chromophore centred on λ= 278 nm, and by LCMS (see below).
LCMS. The HPLC system described above was coupled to a Bruker Daltonics
Esquire 3000 electrospray mass spectrometer. Chromatography was achieved over
a Phenomenex HyperClone C18-BDS column (150 × 4.6 mm, 3 μm particle size) or
Phenomenex Gemini-NX C18 110 Å reversed-phase column (150 × 4.6 mm, 3 μm
particle size). Samples were eluted at a ﬂow rate of 1 mLmin−1 with either gradient
A: mobile phase A: mobile phase B (90:10) to (0:100) over 20 min; or gradient B:50
% mobile phase B to 100% mobile phase B over 10 min followed by an isocratic
hold at 100% mobile phase B for 3 min. Mobile phase A was water containing 0.1%
formic acid and mobile phase B was acetonitrile containing 0.1% formic acid.
Positive/negative ion mode switching was used and spectra were acquired between
m/z values of 500−1000.
Larger-scale fermentation and rapalog isolation. Seed cultures were prepared by
inoculating spore stocks at 0.05% (w/v) inoculum into 400 mL medium RapV7 in 2
L Erlenmeyer ﬂasks ﬁtted with foam plugs. After 48 h at 28 °C, 250 r.p.m. (2.5 cm
throw) each seed culture was transferred into 15 L of medium MD6/5–1, pre-
adjusted to pH 6.0–7.0 in a V7 Braun 22 L fermenter19. Fermentation was carried
out for 6 days at 26 °C with initial agitation at 200 r.p.m., aeration rate at 0.5 V/V/
M and dissolved oxygen (DO) level controlled with the agitation cascade at 30% air
saturation. For production hCHCA dissolved in methanol (3–5 mL) was added to
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the production medium 24 h after inoculation to give a ﬁnal concentration of 2
mM. After ﬁve further days the whole broth was centrifuged at 3300×g for 25 min.
The cell pellet was removed from the centrifuge pots by mixing with acetonitrile
and decanting into a 10 L glass Duran. Further acetonitrile was added to give a ratio
of 2 vol. of solvent to 1 vol. of cells. The mixture was then stirred for 1 h using an
overhead electric paddle stirrer at 600 r.p.m. After 1 h stirring was halted and the
mixture allowed to settle under gravity for 15 min. The solvent layer was removed
and a further 2 vol. of acetonitrile added to the remaining cells. This was stirred
again to obtain a second extract. Any target compound in the supernatant fraction
was recovered by adding an equal volume of ethyl acetate and stirring for 1 h in a
glass container using an overhead electric paddle stirrer at 600 r.p.m. The organic
solvent was then separated by centrifugation at 3300×g for 15 min. The combined
extracts from both the cell pellet and, if required, clariﬁed broth, were concentrated
in vacuo to give a residual aqueous extract which was then back extracted into an
equal volume of ethyl acetate. A second ethyl acetate extraction was performed if
required. The ethyl acetate extract containing the target rapalogs was then con-
centrated in vacuo to yield a ﬁnal crude extract sample. The crude extract was
dissolved in 1:1 methanol/acetonitrile (v/v) and C18 reverse-phase silica added.
The solvent was removed in vacuo and the silica added to a C18 reverse-phase
silica open column (70 × 50 mm diameter) and the column eluted step-wise with
3:2 water/acetonitrile (600 mL), 1:1 water/acetonitrile (400 mL), 2:3 water/acet-
onitrile (v/v) (1000 mL). Fractions containing rapalogs were pooled and taken to
dryness under reduced pressure.
Rapalogs were isolated by dissolving the enriched extract in methanol (5 mL)
and separating the mixture by size-exclusion chromatography over Sephadex LH-
20 (column dimensions 1000 × 30mm diameter) eluting with methanol. Fractions
containing rapalogs were combined and the solvent removed under reduced
pressure. The residue was dissolved in a minimum volume of acetonitrile and
adsorbed onto C18 reverse-phase silica. This was then added to a C18 silica column
(100 × 30mm diameter) and eluted with 3:2 (v/v) acetonitrile/water. The fractions
containing compounds of interest were combined and taken to dryness under
reduced pressure.
Alternatively, the dried crude extract was dissolved in ethyl acetate and normal
phase silica gel 60 added. The solvent was removed in vacuo and the silica added to
a silica gel 60 open column (300 × 25mm diameter) and the column eluted with
chloroform followed by an increasing methanol concentration to 5% in 1% steps.
Fractions containing rapalogs were pooled and the solvent removed under reduced
pressure. Final puriﬁcation was effected by prep HPLC using a Gilson system with
a Waters X Terra C18 column (19 × 250mm, 10 μm particle size). Samples were
chromatographed using a gradient of water and acetonitrile (50:50) to (0:100) over
25 min at a ﬂow rate of 21 ml min−1. Fractions containing rapalogs were pooled
and the solvent removed under reduced pressure.
Mutasynthesis of rapalogs. A variety of carboxylic acid feeds were added to the
fermentation broths19. The starter units tested were: cyclohexanecarboxylic acid,
cyclohex-1-enecarboxylic acid, cyclohex-3-enecarboxylic acid,
3-methoxycyclohexanecarboxylic acid, ethyl 5-hydroxycyclohex-3-enecarboxylic
acid, (1s*,3S*,4R*)−4-ﬂuoro-3-hydroxycyclohexanecarboxylic acid,
4-methylcyclohexanecarboxylic acid, cyclopentanecarboxylic acid, cycloheptane-
carboxylic acid, (1R*,2S*,4S*)-bicyclo[2.2.1]heptane-2-carboxylic acid,
(1S*,2R*,5R*,6S*)−2-hydroxybicyclo[3.2.1]octane-6-carboxylic acid, tetrahydro-
2H-pyran-4-carboxylic acid, tetrahydro-2H-thiopyran-4-carboxylic acid,
3-hydroxybenzoic acid, 4-methylthiophene-2-carboxylic acid, 3-amino-5-
hydroxybenzoic acid, 4-hydroxy-3,3-dimethylcyclohexanecarboxylic acid,
4-methylenecyclohexanecarboxylic acid, 4-methylcyclohex-3-enecarboxylic acid,
(1S*,4S*)−4-methylcyclohexanecarboxylic acid, (1S*,3S*,4S*)−3,4-dihydrox-
ycyclohexanecarboxylic acid, 3-methylcyclohexanecarboxylic acid, isonicotinic
acid, 5-methylthiophene-2-carboxylic acid, cyclohexanecarboxylic acid, (1R*,4R*)
−4-hydroxycyclohexanecarboxylic acid, (2S*)-bicyclo[2.2.1]heptane-2-carboxylic
acid, (1S*,3S*)−3-hydroxycyclohexanecarboxylic acid, (1S*,3R*,4S*)-methyl
3-ﬂuoro-4-hydroxycyclohexanecarboxylate, (1S*,3R*,4S*)−3-ethyl-4-hydro-
xycyclohexanecarboxylic acid, methyl 3,3-diﬂuoro-4-hydro-
xycyclohexanecarboxylate, (1S*,3R*)−3-hydroxycyclohexanecarboxylic acid. These
were either purchased from Sigma, Alfa Aesar, Fisher Scientiﬁc or synthesised
using standard methods (Supplementary Note 2).
Analysis of temperature sensitive replicon importance for AE. To test the
importance of the temperature sensitive replicon for recombination, conjugative
plasmids containing identical regions of homology to the tylosin PKS genes (a
2035 bp fragment covering the KR and ACP domains of module 2) were generated
for pKC1139 and the closely related suicide vector pKC1132 which lacks the pSG5
replicon21 and both were used for AE of the tylosin PKS. Following the AE pro-
cedure with the pSG5-based plasmid, 67% (20) of the isolated progeny produced
new peaks assessed to be new tylosin analogues by LCMS/UV methods described
above, and 33% (10) lacked tylosin or analogue production. When the control
plasmid was used, no strains produced new tylosin analogues. Instead, 70% (21)
reverted to tylosin production (wild-type) and 30% (9) were non-producers; none
produced any tylosin analogues.
FKBP12 PPIase inhibition assay. The assay was conducted at 10 °C in 50 mM Tris
buffer at pH 8.0, 50 µM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and
60 µM substrate (SUC-ALPF-pNA, diluted from 20mgmL−1 stock in 0.5 M LiCl/
TFE). The Km for the substrate was determined to be ~188 µM. The ﬁrst order rate
equation was ﬁtted to the absorbance data to obtain a rate constant. A catalytic rate
(Kenz) was calculated from the enzymatic rate minus the background rate. Kenz vs.
inhibitor concentration was plotted to obtain the Ki value. All compounds were
assayed at 6 concentrations in duplicate. The assay was conducted at Selcia Ltd,
Ongar UK (http://www.selcia.com/sites/default/ﬁles/
Selcia_Prolyl_Isomerases_Paper_2015.pdf).
mTORC1 inhibition measurement. A commercially available Cellular RpS6
phospho-S6RP (Ser 235/236) HTRF assay (Homogeneous Time Resolved Fluor-
escence or TR-FRET assay; Cisbio, Codolet, France) was used according to the
manufacturer’s instructions. Brieﬂy, genome-edited human TSC2(−/−) embryonic
neural stem cells, were grown in 384-well plates, coated with p-Ornithin and
laminin, at 6000 cells per well. Plates were incubated overnight at 37 °C and 5%
CO2, serum starved for 5 h, and treated with compounds for 1 h at 37 °C and 5%
CO2. Compounds were serially diluted 2.5-fold, for a 16 point dose-response with a
range from 100 µM to 671 pM. Cells were lysed using 10 μL of 4X assay lysis buffer
for 1 h at room temperature, and 8 μL of the total lysate was transferred to a white
384-well assay plate (Costar 3825). After the addition of both d2-labelled anti-S6
and cryptate labelled anti-phospho-S6 antibody to each well, the mixtures were
incubated at room temperature for 3 h. Emission levels at 620 and 665 nm were
measured using a Paradigm multilabel plate reader (Molecular Devices). FRET
ratios were determined by calculation of emission ratios (665 nm/620 nm).
Burkholderia pseudomallei PPIase inhibition assay. The PPIase activity of
recombinant BPSS1823 protein was determined by a protease-coupled assay28. For
inhibition measurements, recombinant BPSS1823 protein was preincubated with
various concentrations of test article from 100 to 1 nM for 6 min prior to the
addition of substrate. At least three independent readings were taken at each data
point.
Saccharomyces cerevisiae MIC assay. Minimum Inhibitory Concentration (MIC)
values for each compound were determined using the microdilution method.
Brieﬂy, stock solutions of the 6 test rapalogs (6.4 mg mL−1 in methanol) were
diluted 1:50 in RPMI 1640 broth (Sigma-Aldrich) to a working concentration of
128 µg ml−1, and serially diluted in broth (1:2) in sterile, polypropylene 96-well
plates, 100 µL per well. Saccharomyces cerevisiae was cultured in RPMI 1640 broth,
37 °C, 250 r.p.m., 18 h. The culture was diluted in broth to achieve a cell density of
approx. 106 CFU/mL. A volume of 100 µL aliquots of this dilution were added to
each well and mixed by gentle trituration. Plates were incubated at 37 °C for 24 h.
The concentration of compound at which no visible growth was apparent was
determined to be the MIC. For concentrations at which growth was markedly
reduced but not completely inhibited the microorganism was recorded as being
susceptible.
Assessment of purity for isolated rapalogs. Puriﬁed compounds were analysed
using HPLC-UV/MS and two independent chromatography systems. Purity was
assessed by LCMS and by UV absorbance at multiple wavelengths (210, 254 and
278 nm). All compounds were >95% pure at all wavelengths. Purity was ﬁnally
conﬁrmed by inspection of the 1H and 13C NMR spectra.
NMR structure elucidation methods. NMR spectra were recorded on a Bruker
Advance 500 spectrometer at 298 K operating at 500MHz and 125MHz for 1H
and 13C, respectively. Standard Bruker pulse sequences were used to acquire 1H
−1H COSY, APT, HMBC and HMQC spectra. NMR spectra were referenced to the
residual proton or standard carbon resonances of the solvents in which they were
run.
Sequencing and analysis of recombinant PKS clusters. S. rapamycinicus strains
were cultured in TSB medium and S. fradiae were cultured in CSM medium (30 g/L
tryptic soy broth, 3 g/L yeast extract, 2 g/L MgSO4, 5 g/L glucose and 4 g/L mal-
tose). The high molecular weight total genomic DNA was isolated using the salting
out procedure49.
PacBio RSII sequencing was carried out as a service by the Earlham Institute
(Norwich Research Park, Norwich, UK). Libraries were prepared using Paciﬁc
Biosciences DNA Template Prep Kit 3.0. Library size selection was carried out
using MagBead OneCellPerWell v1. Sequencing was carried out on the PacBio RSII
platform, using P6-C4 chemistry, and using 4 SMRT cells for each strain.
TruSeq PCR-free shotgun and Nextera matepair libraries were constructed from
high molecular weight genomic DNA, using the manufacturer’s protocol.
Sequencing was carried out on an Illumina MiSeq platform using the Illumina V3
600 cycle kit run in 2 × 300 bp mode. Eight libraries were multiplexed in a single
run. Reads were processed using an in-house Illumina adapter trimming tool
(fastq_miseq_trimmer). Read pairs were then pre-assembled using FLASH v1.2.11
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(https://ccb.jhu.edu/software/FLASH/). Nextera matepair linker sequence was used
for splitting of matepair reads (fastq_miseq_trimmer).
Recombinant cluster assembly from Illumina reads. Both mapping and de novo
assemblies were used to obtain a reference sequence for the recombinant PKS
clusters, using the reads from Illumina platform. Processed reads were assembled
de novo using Newbler v3 (Roche). Several assemblies were carried out using either
all or subsets of the input data set, and the best assembly was selected using a score
calculated from scaffold N50, edge and total number of contigs. Mapping to the
cluster reference was carried out using Newbler v3 and the results were saved in ace
and bam formats. At least two mapping projects (PCR-free and PCR-free + Nextera
matepair reads) were created for each consensus version.
The mapping results were post-processed by an in-house ballﬁx program (to ﬁx
the paired reads metadata in the phd.ball ﬁle) and visualised using consed
v29 software [www.phrap.org]. Copy number variations were visually detected
using consed’s assembly view as changes in the coverage of PCR-free reads. Each
consensus was reconﬁrmed by a ﬁnal round of mapping.
Recombinant cluster assembly from PacBio reads. PacBio reads ware assembled
de novo using SMRT analysis pipeline v.2.2 (https://github.com/PaciﬁcBiosciences/
SMRT-Analysis) with a single pass of consensus polishing using Quiver.
Annotation of the recombinant clusters. Prediction of PKS/NRPS domains was
carried out using an in-house version of the secmetdb pipeline (https://sourceforge.
net/projects/secmetdb/). The DNA sequence of the domains was exported into the
NCBI BLAST database and used for annotation of the domains in the recombinant
strains using (annot_blast_mapper) and NCBI blastall v2.2.17. Open reading frame
annotation was transferred from the reference parent cluster using the RATT
pipeline (http://www.sanger.ac.uk/science/tools/pagit).
All sequences have been submitted to Genbank and are available under the
accession numbers KY457762, KY457763, KY457764, KY457765, KY457766,
KY457768, KY457769, KY457770, KY457771, KY457772, KY457773, KY457774,
KY457775, KY457776, KY457777, KY457778, KY457779, KY457780 KY650706,
KY650707, KY650708, KY650709, KY650710, KY650711, KY650712, KY650713,
KY650714 and KY650715.
Detection of recombination hotspots. Detection of potential recombination sites
was carried out using the (annot_recomb_mapper) pipeline based on NCBI blastn
v.2.2.17, run in master/slave mode. The results were saved in the Artemis feature
format (*.tab) and combined with all other annotation information. Final junctions
were deﬁned as regions of the translated hybrid rapamycin or tylosin PKS genes
where the amino acid sequence upstream of the junction had identity to one
module but the downstream sequence had at least two amino acids which were not
identical to that module, but were identical to the amino acid sequence from
another non-sequential module of the PKS. Annotation results were combined in
EMBL format (tab2embl) and visualised and manually curated in Artemis (http://
www.sanger.ac.uk/science/tools/artemis).
Data availability. The authors declare that the data supporting the ﬁndings
reported in this study are available within the article and the Supplementary
Information, or are available from the authors upon reasonable request. New
nucleotide sequence data have been deposited in NCBI GenBank under the
accession codes: KY457762, KY457763, KY457764, KY457765, KY457766,
KY457768, KY457769, KY457770, KY457771, KY457772, KY457773, KY457774,
KY457775, KY457776, KY457777, KY457778, KY457779, KY457780 KY650706,
KY650707, KY650708, KY650709, KY650710, KY650711, KY650712, KY650713,
KY650714 and KY650715.
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